Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes

Kuang, Xingyi; Chi, Jianxiang; Wang, Li

doi:10.1080/10245332.2016.1193962

Cited by 18 publications

(20 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 107 It has been found that miR181c, miR181a, miR181b, and miR181d are selectively overexpressed in high-risk cases of MDS. 108 The literature also reports upregulation of miR720 and miR21, whereas levels of miR210 and miR155 are increased in CD34 + MDS cells. 109 – 111 At the same time, decreased expression of the Let7 family of microRNAs was shown.…”

Section: Microrna Expression In Chronic Myelogenous Leukemiamentioning

confidence: 99%

Abnormal microRNA expression in the course of hematological malignancies

Szymczyk¹,

Macheta²,

Podhorecka³

2018

CMAR

View full text Add to dashboard Cite

Research on the carcinogenesis process is currently focused primarily on understanding its genetic basis and molecular abnormalities that may be predictive factors and therapeutic targets. It was clearly confirmed recently that microRNAs are involved in the mechanisms of leukocyte development, differentiation, and apoptosis, as well as in the pathogenesis of proliferative diseases of the hematopoietic system. Currently, research strategies allow determination of the deregulation of microRNA profiles in relation to other cytogenetic aberrations, as well as prognostic factors and primary end points. The problem of the possibility of their use as therapeutic targets is also increasingly discussed. In this article, we analyze literature data on abnormalities in microRNA expression in proliferative diseases of the hematopoietic system in the context of classic cytogenetic and molecular aberrations.

show abstract

Section: Microrna Expression In Chronic Myelogenous Leukemiamentioning

confidence: 99%

Abnormal microRNA expression in the course of hematological malignancies

Szymczyk¹,

Macheta²,

Podhorecka³

2018

CMAR

View full text Add to dashboard Cite

show abstract

“…Given their regulatory role, miRNAs have been evaluated in samples obtained from MDS patients, sAML patients, and healthy donors. Comparative studies revealed a differential miRNA expression pattern between these three groups [ 16 , 92 ] ( Table 1 ). These studies were carried out to identify (i) diagnostic and prognostic markers for these diseases, (ii) biomarkers indicative of the progression from MDS to sAML, and (iii) novel therapeutic targets.…”

Section: Mirna Expression In Mds and Samlmentioning

confidence: 99%

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Bauer

Vaxevanis

Heimer

et al. 2020

IJMS

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS), heterogeneous diseases of hematopoietic stem cells, exhibit a significant risk of progression to secondary acute myeloid leukemia (sAML) that are typically accompanied by MDS-related changes and therefore significantly differ to de novo acute myeloid leukemia (AML). Within these disorders, the spectrum of cytogenetic alterations and oncogenic mutations, the extent of a predisposing defective osteohematopoietic niche, and the irregularity of the tumor microenvironment is highly diverse. However, the exact underlying pathophysiological mechanisms resulting in hematopoietic failure in patients with MDS and sAML remain elusive. There is recent evidence that the post-transcriptional control of gene expression mediated by microRNAs (miRNAs), long noncoding RNAs, and/or RNA-binding proteins (RBPs) are key components in the pathogenic events of both diseases. In addition, an interplay between RBPs and miRNAs has been postulated in MDS and sAML. Although a plethora of miRNAs is aberrantly expressed in MDS and sAML, their expression pattern significantly depends on the cell type and on the molecular make-up of the sample, including chromosomal alterations and single nucleotide polymorphisms, which also reflects their role in disease progression and prediction. Decreased expression levels of miRNAs or RBPs preventing the maturation or inhibiting translation of genes involved in pathogenesis of both diseases were found. Therefore, this review will summarize the current knowledge regarding the heterogeneity of expression, function, and clinical relevance of miRNAs, its link to molecular abnormalities in MDS and sAML with specific focus on the interplay with RBPs, and the current treatment options. This information might improve the use of miRNAs and/or RBPs as prognostic markers and therapeutic targets for both malignancies.

show abstract

“…MDS is regarded as a disease preceding leukemia and about 30% of patients with MDS eventually develop AML [ 24 ]. Analysis of literature data showed that miRNA expression profiles differ between early and advanced stages of MDS, suggesting the involvement of miRNAs in the pathogenesis of MDS and, consequently, in MDS-to-AML transformation [ 99 ]. The expression levels of miRNA-27a-3p, −150-5p, −199a-5p, −223-3p and miRNA-451a are reduced in the plasma of high-risk patients with MDS, while miRNA-196b-5p is enhanced in BM specimens from a higher-risk patient with MDS, suggesting that these miRNAs may be used as biomarkers predicting the risk of further transformation of MDS [ 100 , 101 ].…”

Section: Mirna In the Prognosis Of Mdsmentioning

confidence: 99%

Prognostic Markers of Myelodysplastic Syndromes

et al. 2020

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interplay between genetic and epigenetic factors, including miRNA. In practice, karyotype analysis assigns patients to different prognostic groups, and mutations are often associated with a particular disease phenotype. Among myeloproliferative disorders, secondary MDS is a group of special entities with a typical spectrum of genetic mutations and cytogenetic rearrangements resembling those in de novo MDS. This overview analyzes the present prognostic systems of MDS and the most recent efforts in the search for genetic and epigenetic markers for the diagnosis and prognosis of MDS.

show abstract

Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes

Cited by 18 publications

References 85 publications

Abnormal microRNA expression in the course of hematological malignancies

Abnormal microRNA expression in the course of hematological malignancies

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

Prognostic Markers of Myelodysplastic Syndromes

Contact Info

Product

Resources

About